Drugs under investigation for attention-deficit hyperactivity disorder

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1207-1211

  Schweitzer, Julie B ^a   Holcomb, Henry H ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

ADHD; Non stimulant; Psychopharmacology; Stimulant

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CIPRALISANT; DEXAMPHETAMINE; DONEPEZIL; DRUG METABOLITE; GT 2331; HISTAMINE H3 RECEPTOR ANTAGONIST; METHYLPHENIDATE; MODAFINIL; NORADRENALIN UPTAKE INHIBITOR; PERCEPTIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANXIETY; APPETITE DISORDER; ASTHENIA; ATTENTION DEFICIT DISORDER; AVOIDANCE BEHAVIOR; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ABUSE; DRUG APPROVAL; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEADACHE; HUMAN; NARCOLEPSY; NEUROLOGIC DISEASE; NONHUMAN; NORADRENERGIC SYSTEM; OPTIMAL DRUG DOSE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRESCRIPTION; PSYCHOPHARMACOLOGY; RESTLESSNESS; REVIEW; RHINITIS; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREATMENT PLANNING; VERTIGO;

ANIMALS; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS; CYCLOBUTANES; HISTAMINE AGONISTS; HUMANS; INDANS; NOOTROPIC AGENTS; PIPERIDINES; PROPYLAMINES;

EID: 0036707263     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. American Psychiatric Association, Washington, DC, USA (1994).
2. Barkley RA: Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 2nd Edition. (1998). Classic reference on the assessment and treatment of ADHD.
3. Weiss G, Hechtman L (Eds): Hyperactive Children Grown Up. Guilford Press, New York, NY, USA (1993).
4. Biederman J: A 55-year-old man with attention-deficit/hyperactivity disorder. J Am Med Assoc (1998) 280:1086-1092. Overview of assessment and treatment of adult ADHD; Includes response to controversies regarding the diagnosis in adults.
5. Aylward EH, Reiss AL, Reader MJ, Singer HS, Brown JE, Denckla MB: Basal ganglia volumes in children with attention-deficit hyperactivity disorder. J Child Neurol (1996) 11:112-115.
6. Bush G, Frazier JA, Rauch SL, Seidman LJ, Whalen PJ, Jenike MA, Rosen BR, Biederman J: Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biol Psychiatry (1999) 45:1542-1552.
7. Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SC, Simmons A, Bullmore ET: Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: A study with functional MRI. Am J Psychiatry (1999) 156:891-896.
8. Schweitzer JB, Faber TL, Grafton ST, Tune LE, Hoffman JM, Kilts CD: Alterations in the functional anatomy of working memory in adult attention deficit hyepractivity disorder. Am J Psychiatry (2000) 157:278-280.
9. Zametkin AJ, Nordahl TE, Gross M, King AC, Semple WE, Rumsey J, Hamburger S, Cohen RM: Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med (1990) 323:1361-1366.
10. Lou HC, Henriksen L, Bruhn P: Focal cerebral hypoperfusion in children with dysphasia and/or attention deficit disorder. Arch Neurol (1984) 41:825-829.
11. Lou HC, Henriksen L, Bruhn P, Borner H, Nielsen JB: Striatal dysfunction in attention deficit and hyperkinetic disorder. Arch Neurol (1989) 46:48-52.
12. Metochik JA, Nordahl TE, Gross M, Semple WE, King AC, Cohen RM, Zametkin AJ: Effects of acute stimulant medication on cerebral metabolism in adults with hyperactivity. Neuropsychopharmacol (1993) 8:377-386.
13. Teicher MH, Anderson CM, Polcari A, Glod CA, Maas LC, Renshaw PF: Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nat Med (2000) 6:470-473.
14. Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, Gabrieli JD: Selective effects of methylphenidiate in attention deficit hyperactivity disorder: A functional magnetic resonance study. Proc Natl Acad Sci USA (1998) 95:14494-14499.
15. Arnsten AF: Genetics of childhood disorders: XVIII. ADHD, Part 2: Norepinephrine has a critical modulatory influence on prefrontal cortical function. J Am Acad Child Adolesc Psychiatry (2000) 39:1201-1203.
16. Solanto MV: Dopamine dysfunction in AD/HD: Integrating clinical and basic neuroscience research. Behav Brain Res (2002) 130:65-71. Reviews research on the involvement of dopamine in ADHD symptoms and pharmacological treatment.
17. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S: Pharmacotherapy of attention-deficit hyperactivity disorders across the life cycle. J Am Acad Child Adolesc Psychiatry (1996) 35:409-432.
18. Barkley RA: A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry (1977) 18:137-165.
19. Gittelman R: Indications for the use of stimulant treatment in learning disorders. J Am Acad Child Psychiatry (1980) 19:623-636.
20. Biederman J, Spencer T: Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry (1999) 46:1234-1242. Reviews support for a theory linking dysregulated noradrenergic networks to ADHD.
21. MichelsonD,Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose- response study. Pediatrics USA (2001) 108:E83. Largest controlled study to date examining the effects of atomoxetine in children.
22. Michelson D, Wernicke J, Heiligenstein J, Spencer T, Allen A, Faries D: LY139603 (Tomoxetine), a new non-dopaminergic intervention for ADHD. 41st Annual NCDEU Meeting, Phoenix, AZ, USA, May 28-31 (2001).
23. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L: Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry (1998) 155:693-695. Double-blind, placebo-controlled study of atomoxetine in ADHD adults.
24. Kratochvil C, Vaughan B, Bohac D, May D, Harrington M, Baker N et al: Long-term efficacy of tomoxetine for pediatric ADHD: 1 year data. 41st Annual NCDEU Meeting, Phoenix, AZ, USA, May 28-31 (2001).
25. Wernicke J, Faries D, Heiligenstein J, Kelsey G, Kendrick K, Michelson D: Safety of tomoxetine in clinicla trials. 41st Annual NCDEU Meeting, Phoenix, AZ, USA, May 28-31 (2001).
26. Kratochvil CJ, Bohac D, Harrington M, Baker N, May D, Burke WJ: An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol (2001) 11:167-170.
27. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S: An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol (2001) 11:251-265. Study of atomoxetine in children with ADHD.
28. Laws HF, Heil S, Bickel S, Faries D, Badger G: Subjective responses to LY139603 (Tomoxetine) and methylphenidate. 41st Annual NCDEU Meeting, Phoenix, AZ, USA, May 28-31 (2001).
29. 3 receptor agonists and antagonists. Trends Pharmacol Sci (1998) 19:177-183.
30. Passani MB, Bacciottini L, Mannaioni PF, Blandina P: Central histaminergic system and cognition. Neurosci Biobehav Rev (2000) Review of literature supporting relevance of histamine to learning and ADHD.
31. 3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res (2002) 131:151-161.
32. 3 receptor antagonists and ADHD therapeutics. Abstr Soc Neurosci (1996) 22: Abs 18.3.
33. Wesnes KA, Garratt C, Wickens M, Gudgeon A, Oliver S: Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. Br J Clin Pharmacol (2000) 49:110-117.
34. Berquin PC, Giedd JN, Jacobsen LK, Hamburger SD, Krain AL, Rapoport JL, Castellanos FX: Cerebellum in attention-deficit hyperacitivity disorder: A morphometric MRI study. Neurology (1998) 50:1087-1093.
35. Schweitzer JB, Lee DO, Ely TD, Grafton ST, Ostrowitz M, Hanford RB et al: The effects of methylphenidate on the functional neuroanatomy of working memory in ADHD. Abstr Soc Neurosci (1998) 24:Abs 375.12.
36. Schuh LM, Schuster CR, Hopper JA, Mendel CM: Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology (2000) 147:339-346.
37. Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML: Sibutramine: A new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol (1998) 18:231-236.
38. Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K: The vigilance promoting drug modafinil increase dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanisms. Eur J Pharmacol (1996) 306:33-39.
39. Lin JS, Hou Y, Jouvet M: Potential brain neuronal targets for amphetamine, methylphenidate, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA (1996) 93:14128-14133.
40. Engber TM, Dennis SA, Jones BE, Miller MS, Contreras PC: Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: Comparison with amphetamine. Neuroscience (1998) 87:905-911.
41. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM: Dopmainergic role in stimulant-induced wakefulness. J Neurosci (2001) 21:1787-1794. Study demonstrating that modafinil and amphetamine increase dopamine.
42. Taylor FB, Russo J: Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol (2000) 10:311-320. Comparative study of modafinil to dextroamphetamine.
43. Rugino TA, Copley TC: Effects of modafinil in children with attention-deficit/hyperactivity disorder: An open-label study. J Am Acad Child Adolesc Psychiatry (2001) 40:230-235.
44. Menza MA, Kaufman KR, Castellanos A: Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry (2000) 61:378-381.
45. Jasinski DR, Kovacevic-Ristanovic R: Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol (2000) 23:149-156.
46. Jasinski DR: An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol (2000) 14:53-60.
47. Levin ED, Rezvani AH: Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol (2000) 393:141-146.
48. Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince JB, Monuteaux BA, Soriano J, Fine C, Abrams A, Rater M, Polisner D: A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry (1999) 156:1931-1937.
49. Wilens TE, Biederman J, Wong J, Spencer TJ, Prince JB: Adjunctive donepezil in attention deficit hyyperactivity disorder youth: Case series. J Child Adolesc Psychopharmacol (2001) 10:217-222.
50. Abbott Laboratories: Drug development pipeline: ABT-418 . Company Communication January 02 January 02
51. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology (2001) 57:489-495.